Literature DB >> 10052686

Appearance of islet cell autoantibodies after clinical diagnosis of diabetes mellitus.

M Landin-Olsson1, H J Arnqvist, G Blohmé, B Littorin, F Lithner, L Nyström, B Scherstén, G Sundkvist, L Wibell, J Ostman, A Lernmark.   

Abstract

Islet cell antibodies (ICA) and glutamic acid decarboxylase antibodies (GAD65Ab) are often present at diagnosis of insulin dependent diabetes mellitus (type I diabetes) and are supposed to decline in level and frequency during the first years of disease. We have analysed ICA and GAD65Ab at onset and after one year in 395 population based randomly selected 15-34 year old patients newly diagnosed with diabetes mellitus, to study how these autoantibodies persist, disappear and appear and their relation to C-peptide levels. Of the 395 samples 212 (54%) were positive for ICA, 250 (63%) were positive for GAD65Ab and 170 (43%) were positive for both. At follow up after one year, 27/183 (15%) of the ICA negative patients and 25/145 (17%) of the GAD65Ab negative patients had converted to positivity. Among the 103 patients negative for both ICA and GAD65Ab, 16 turned positive for one or both antibodies after one year. Patients converting to positivity for one or the other antibody after one year, had lower C-peptide levels after one year than patients who initially were and remained negative, supporting the hypothesis that these patients have a genuine type I diabetes. In conclusion, newly diagnosed patients may be negative for autoantibodies at diagnosis but develop these antibodies later on during the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052686     DOI: 10.3109/08916939908995973

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  5 in total

1.  Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adult people (15-34 yrs) in the Diabetes Incidence Study in Sweden (DISS).

Authors:  H Borg; H J Arnqvist; E Björk; J Bolinder; J W Eriksson; L Nyström; J-O Jeppsson; G Sundkvist
Journal:  Diabetologia       Date:  2003-02-08       Impact factor: 10.122

2.  HLA-DQB1 genotypes, islet antibodies and beta cell function in the classification of recent-onset diabetes among young adults in the nationwide Diabetes Incidence Study in Sweden.

Authors:  E Bakhtadze; H Borg; G Stenström; P Fernlund; H J Arnqvist; A Ekbom-Schnell; J Bolinder; J W Eriksson; S Gudbjörnsdottir; L Nyström; L C Groop; G Sundkvist
Journal:  Diabetologia       Date:  2006-05-31       Impact factor: 10.122

3.  Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes.

Authors:  K Decochez; I Truyen; B van der Auwera; I Weets; E Vandemeulebroucke; I H de Leeuw; B Keymeulen; C Mathieu; R Rottiers; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2005-03-09       Impact factor: 10.122

4.  Relationship between Ljungan virus antibodies, HLA-DQ8, and insulin autoantibodies in newly diagnosed type 1 diabetes children.

Authors:  Anna-Lena Nilsson; Fariba Vaziri-Sani; Cecilia Andersson; Karin Larsson; Anneli Carlsson; Elisabeth Cedervall; Björn Jönsson; Jan Neiderud; Helena Elding Larsson; Sten-Anders Ivarsson; Åke Lernmark
Journal:  Viral Immunol       Date:  2013-05-17       Impact factor: 2.257

5.  Development and Standardization of an Improved Type 1 Diabetes Genetic Risk Score for Use in Newborn Screening and Incident Diagnosis.

Authors:  Seth A Sharp; Stephen S Rich; Andrew R Wood; Samuel E Jones; Robin N Beaumont; James W Harrison; Darius A Schneider; Jonathan M Locke; Jess Tyrrell; Michael N Weedon; William A Hagopian; Richard A Oram
Journal:  Diabetes Care       Date:  2019-02       Impact factor: 17.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.